Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, reported first-quarter 2026 operational highlights and financial results, demonstrating a 47% year-over-year reduction in research and development spending while advancing multiple clinical programs through key regulatory milestones.
The company achieved a successful FDA Type C meeting outcome for the Phase 2 HARMONIC trial of LP-300 and received IND clearance for Starlight Therapeutics’ first pediatric CNS cancer program. Lantern also launched withZeta.ai, its multi-agentic AI drug development platform, which is now commercially available as a subscription-based research platform for the global biomedical community, representing a new revenue stream.
Recent financing of up to $9.25 million extends the company's operating runway into the first quarter of 2027, providing additional capital to support its clinical pipeline and AI commercialization strategy. The company also outlined plans to separate its AI assets into an independent entity.
Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas. For more information, visit the company's newsroom at https://ibn.fm/LTRN.
